… evidence regarding chloroquine for the treatment of COVID-19. … safety from long-time clinical
use for other indications to justify clinical research on chloroquine in patients with COVID-19…

… observational study Patients with SLE and COVID-19 (n = 80) HCQ or chloroquine (in use
prior to COVID-19 for other clinical reasons) (n = 51) No HCQ or chloroquine regimens (n = 29…

… benefit for chloroquine or hydroxychloroquine in the treatment of COVID-19 are likely …
were recently reported to benefit a subset of patients with COVID-19 [50-52]. Additionally, some …

… available, the off-label use of CQ/HCQ should be reserved only for COVID-19 patients
treated in context of clinical trials in order to improve our knowledge on safety and efficacy. …

… clinical utility of chloroquine and hydroxychloroquine in treating COVID-19. … chloroquine in
treating COVID-19. Hydroxychloroquine is a derivative of chloroquine with an improved safety …

… , this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests
that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic. …

… COVID-19 pneumonia. However, several safety concerns have been raised from chloroquine
… a critical appraisal of the safety information regarding chloroquine treatment and to apply …

… that CQ or HCQ does not improve clinical outcomes in COVID-19. Well-designed randomized
trials are required for assessing the efficacy and safety of HCQ and CQ for COVID-19. …

… chloroquine phosphate, an old drug for treatment of malaria, had demonstrated marked efficacy
and acceptable safety in treating COVID-19 … , chloroquine was found to block COVID-19 …

… antiviral and immunomodulatory options for the treatment of 2019 coronavirus disease (COVID-19).
To examine the safety profiles of these medications, we systematically evaluated the …